乳腺癌组织中HER-2的表达及其药物治疗策略  

Expressions of HER-2 in breast cancer and strategy of drug treatment

作　　者：施烯[1] 林小燕[1] 黄沂[1] 张志锋[1] 王日雄[1] 曾乌查[1] 郑敏[1] 

机构地区：[1]福建医科大学附属第一医院化疗科,福州350005

出　　处：《海峡药学》2008年第10期96-98,共3页Strait Pharmaceutical Journal

摘　　要：目的探讨乳腺癌组织中HER-2的表达与患者组织学类型、TNM分期、腋窝淋巴结转移、ER和PR间的关系,及HER-2过度表达乳腺癌的药物治疗策略。方法用免疫组织化SP法检测311例乳腺癌组织HER-2的表达。结果1、HER-2阳性表达87例(占27.97%)。2、HER-2的表达与组织学类型、TNM分期无关(P值分别为0.157和0.256)。3、HER-2阳性表达与腋窝淋巴结转移、ER和PR表达降低有关(P值分别为0.032,0.014和0.026)。结论乳腺癌患者HER-2过表达提示预后不良,检测该指标可为化疗、内分泌、靶向治疗提供依据。OBJECTIVE To study the expressions of human epidermal growth factor recepter 2（HER-2） in breast cancer tissues and their clinical significance,strategy of drug treat.METHODS The expressions of HER-2 were detected by immunohistochemistry in 311 cases of breast cancer tissues proved pathologically.RESULTS 1.The positive rates of HER-2 was 27.97% in breast cancer tissues.2.Significant relationships were found among the expressions of HER-2 with axillary nodes metastasis,ER and PR lose status of breat cancer（P=0.032,0.014 and 0.026）.3.The associations among the expression of HER-2 with TNM status,histologic group did not reach statistical significance.CONCLUSION Those findings indicate that overexpression of HER-2 is one of unfavorable prognosis index.The endocrine therapy,targeted therapy and chemotherapy of breast cancer may according to it.

关 键 词：乳腺肿瘤 表皮生长因子受体-2 药物治疗 

分 类 号：R737.9[医药卫生—肿瘤] R969.4[医药卫生—临床医学]